Protas announces collaboration with GSK to advise on optimising protocol development

Protas has formed a multi-year strategic collaboration with GlaxoSmithKline (GSK) to advise on the development of clinical trial protocols across a range of different late-phase investigational products.

Leveraging the Protas team’s vast experience in designing and delivering clinical trials, GSK has engaged Protas to provide valuable complementary expertise and strategic insights to the development of late-phase clinical trial protocols, from the initial conceptualisation of study designs to the approval of the concept protocol.  

Professor Richard Haynes, Chief Scientist at Protas, said: “This really plays to Protas’ strength of designing high-quality, large-scale clinical trials, and being able to support partners right from the start of the process – with the protocol.

“We are thrilled to be working with GSK to help produce robust, streamlined protocols for late-phase clinical trials. Our quality-by-design approach ensures that protocols are both scientifically robust and operationally feasible, facilitating enrolment of diverse patients.

“We are excited by this long-term opportunity, and we are looking forward to working closely with the GSK team throughout the years to come.”

Christopher Corsico, Senior Vice President, Development at GSK, said: “We have an ambitious product pipeline, for which we are using science and advanced technologies to develop new vaccines and medicines.

“We see the immense value of Protas’ expertise and work as a not-for-profit to help us optimise our clinical trials in 2024 and beyond.”